Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial

医学 放化疗 诱导化疗 化疗 胰腺癌 肿瘤科 诱导疗法 随机对照试验 内科学 癌症
作者
Rainer Fietkau,Michael B. Ghadimi,Robert Grützmann,Uwe A. Wittel,Lutz Jacobasch,Waldemar Uhl,Roland S. Croner,Wolf O. Bechstein,Ulf P. Neumann,Dirk Waldschmidt,Stefan Hubert Boeck,Nicolas Moosmann,Anke Reinacher‐Schick,Henriette Golcher,Werner Adler,Sabine Semrau,Dorota Łubgan,Annett Kallies,Markus Hecht,Iris Tischoff
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (30): 3266-3278 被引量:52
标识
DOI:10.1200/jco-24-01502
摘要

PURPOSE To determine the benefit, measured as complete removal of a tumor so that no tumor cells are detectable during histopathologic examination of the resection margin (R0 resection rate), of induction chemotherapy plus chemoradiotherapy (CRT) compared with chemotherapy alone for unresectable pancreatic tumors. PATIENTS AND METHODS CONKO-007, an investigator-initiated open-label, multicentric, phase III randomized clinical trial, enrolled 525 patients with unresectable tumors, and 495 patients received induction chemotherapy (402 with fluorouracil, irinotecan, and oxaliplatin [FOLFIRINOX] and 93 with gemcitabine). Patients without progression after 3 months of induction chemotherapy (n = 336) were randomly assigned for continuation of the same chemotherapy (n = 167) or CRT (n = 169; 50.4Gy concurrently with gemcitabine). Resectability was centrally reassessed by a panel of surgeons. Surgery was recommended if possible. After an interim analysis, the primary end point was changed from overall survival (OS) to overall R0 resection rate because of slow recruitment. The median follow-up was 76 months. Important planned secondary end points were R0 resection rate in the surgically treated population and OS. RESULTS The primary end point (overall R0 resection rate) was not significantly different between treatment arms with 25% (43 of 169) in the CRT arm versus 18% in the chemotherapy arm (30 of 167; P = .113). Secondary end point analysis showed that surgery was performed equally often ( P = .91); R0 resection rate in patients who underwent surgery was higher after CRT, 69.4% (43 of 62) compared with chemotherapy alone: 50.0% (30 of 60 patients, P = .04). Other parameters of resection (ratio of R0/R1/R2/no resection) also favored CRT ( P = .02). No difference in OS was seen between treatment arms (hazard ratio [HR], 0.937 [95% CI, 0.747 to 1.174]; P = .57; randomly assigned intention-to-treat patients). Surgery was associated with longer OS ( P < .001, HR, 0.525 [95% CI, 0.408 to 0.676]). CONCLUSION Although not improving overall R0 resection rate or survival, CRT enables a R0 resection in surgically treated patients more often than chemotherapy alone.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
福yyy发布了新的文献求助10
2秒前
jianghuren发布了新的文献求助10
3秒前
Zz发布了新的文献求助10
4秒前
zxzx发布了新的文献求助10
6秒前
horse完成签到,获得积分10
6秒前
TOT完成签到,获得积分10
7秒前
天天快乐的应助被绪绪采纳,获得10
7秒前
8秒前
10秒前
10秒前
lila完成签到,获得积分10
13秒前
13秒前
13秒前
13秒前
浮生发布了新的文献求助20
14秒前
trx发布了新的文献求助10
14秒前
csy完成签到,获得积分10
15秒前
科目三的应助被孟庆亮采纳,获得10
15秒前
15秒前
15秒前
子夜歌发布了新的文献求助20
17秒前
hoyden完成签到,获得积分10
18秒前
up0818完成签到 ,获得积分10
18秒前
LQY完成签到 ,获得积分10
19秒前
shao发布了新的文献求助10
19秒前
邵蹦蹦发布了新的文献求助10
19秒前
Attendre发布了新的文献求助10
19秒前
20秒前
21秒前
21秒前
兜里有糖完成签到,获得积分10
22秒前
22秒前
22秒前
Seven发布了新的文献求助10
22秒前
25秒前
Maestro_S的应助被科研通管家采纳,获得10
25秒前
niu完成签到 ,获得积分10
25秒前
汉堡包的应助被科研通管家采纳,获得10
25秒前
SciGPT的应助被科研通管家采纳,获得10
25秒前
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186750
求助须知:如何正确求助?哪些是违规求助? 9575027
关于积分的说明 21839240
捐赠科研通 7784331
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559206
邀请新用户注册赠送积分活动 2481611